Information Provided By:
Fly News Breaks for February 28, 2018
ABT, SRDX
Feb 28, 2018 | 08:37 EDT
Lake Street analyst Brooks O'Neil raised his price target for Surmodics (SRDX) to $38 saying the company's strategic agreement with Abbott Laboratories (ABT) is a "game changer." The deal validates Surmodics' "whole products" strategy, and provides both a financial and strategic runway for SurVeil, O'Neil tells investors in a research note. He keeps a Buy rating on the shares.